« Return to News | Drug Sponsors

Cephalon announces takeover bid for ChemGenex

Wednesday, March 30, 2011 01:51 PM

Cephalon and ChemGenex Pharmaceuticals announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings, intends to make a takeover bid for ChemGenex. ChemGenex is a hematology-focused Australian biopharmaceutical company developing its lead product candidate, Omapro, for the treatment of chronic myeloid leukemia (CML) patients. Omapro recently completed phase III clinical trials and ChemGenex plans to file a new drug application with the FDA in the second half of 2011.

Cephalon will pay about $163 million to acquire all the outstanding shares of ChemGenex--the deal values the company at about $225 million, according to Fierce Biotech.

The takeover bid has the support of the ChemGenex all directors who will recommend it to ChemGenex Shareholders and holders of ChemGenex Listed Options in the absence of a superior offer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.